Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction : A Prespecified Analysis of DAPA- HF.

• BACKGROUND: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk of mortality and heart failure (HF) hospitalization. We examined the frequency and significance of episodes of outpatient HF worsening, requiring the augmentation of oral therapy, and the effects of dapagliflozin on these additional events. METHODS: Patients in New York Heart Association functional class II to IV, with a left ventricular ejection fraction

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

Aged

Benzhydryl Compounds/pharmacology/*therapeutic use

Double-Blind Method

Glucosides/pharmacology/*therapeutic use

heart failure

Heart Failure/*drug therapy

hospitalization

Humans

Outpatients

Prospective Studies

sodium-glucose transporter 2 inhibitors

Sodium-Glucose Transporter 2 Inhibitors/pharmacology/*therapeutic use

Stroke Volume/*drug effects

therapy

treatment outcome

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)